Evidence map›Paper›PMID 30528729›Full record

ReviewAdvanced drug delivery reviews2019

Advances in transdermal insulin delivery.

Yuqi Zhang, Jicheng Yu, Anna R Kahkoska, Jinqiang Wang, John B Buse, Zhen Gu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Microneedles: Selected Applications for Pediatrics.Children (Basel, Switzerland) · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuqi ZhangDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA.
Jicheng YuJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA.
Anna R KahkoskaDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
Jinqiang WangDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA.
John B BuseDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
Zhen GuDepartment of Bioengineering, University of California, Los Angeles, CA 90095, USA; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA; California NanoSystems Institute, Jonsson Comprehensive Cancer Center, Center for Minimally Invasive Therapeutics, University of California, Los Angeles, CA 90095, USA. Electronic address: guzhen@ucla.edu.

Funding

Characterizing Impulsivity as a Determinant of Weight and Glycemic Control in Youth with Type 1 DiabetesF30DK113728 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAHKOSKA, ANNA RACHEL · 2017 to 2020
$171k
NIDDK NIH HHS F30 DK113728
6 · The paper itself

Abstract

Insulin therapy is necessary to regulate blood glucose levels for people with type 1 diabetes and commonly used in advanced type 2 diabetes. Although subcutaneous insulin administration via hypodermic injection or pump-mediated infusion is the standard route of insulin delivery, it may be associated with pain, needle phobia, and decreased adherence, as well as the risk of infection. Therefore, transdermal insulin delivery has been widely investigated as an attractive alternative to subcutaneous approaches for diabetes management in recent years. Transdermal systems designed to prevent insulin degradation and offer controlled, sustained release of insulin may be desirable for patients and lead to increased adherence and glycemic outcomes. A challenge for transdermal insulin delivery is the inefficient passive insulin absorption through the skin due to the large molecular weight of the protein drug. In this review, we focus on the different transdermal insulin delivery techniques and their respective advantages and limitations, including chemical enhancers-promoted, electrically enhanced, mechanical force-triggered, and microneedle-assisted methods.

Indexed as

Administration, CutaneousAnimalsElectroporationHumansHypoglycemic AgentsInsulinIontophoresisMicroinjectionsNeedlesUltrasonic WavesHypoglycemic AgentsInsulinDiabetesDrug deliveryElectroporationInsulinIontophoresisJet injectionMicroneedleTransdermal deliveryUltrasound

Identifiers

PMID30528729
PMCPMC6556146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.